In conclusion, the high stability, low clearance, long plasma half-life, and remarkable safety/efficacy profile of CD101 support further development of CD101 as a highly differentiated therapy for the treatment of serious fungal infections. This evidence concerns the gene CD101 and fungal infectious disease.